WO1998048627A1 - Teat dipping agent - Google Patents

Teat dipping agent Download PDF

Info

Publication number
WO1998048627A1
WO1998048627A1 PCT/SE1998/000776 SE9800776W WO9848627A1 WO 1998048627 A1 WO1998048627 A1 WO 1998048627A1 SE 9800776 W SE9800776 W SE 9800776W WO 9848627 A1 WO9848627 A1 WO 9848627A1
Authority
WO
WIPO (PCT)
Prior art keywords
teat
use according
solution
chitosan
polysaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE1998/000776
Other languages
French (fr)
Inventor
Olle Larm
Marcus Back
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicarb AB
Original Assignee
Medicarb AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ333511A priority Critical patent/NZ333511A/en
Priority to JP10546900A priority patent/JP2000515897A/en
Priority to PL98330870A priority patent/PL330870A1/en
Priority to US09/202,930 priority patent/US6630458B2/en
Priority to CA002259327A priority patent/CA2259327A1/en
Priority to AU73548/98A priority patent/AU721692B2/en
Priority to BR9804875-9A priority patent/BR9804875A/en
Priority to EP98920795A priority patent/EP0917427B1/en
Application filed by Medicarb AB filed Critical Medicarb AB
Priority to DK98920795T priority patent/DK0917427T3/en
Priority to AT98920795T priority patent/ATE223649T1/en
Priority to DE69807818T priority patent/DE69807818T2/en
Publication of WO1998048627A1 publication Critical patent/WO1998048627A1/en
Priority to BG103034A priority patent/BG64027B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A01N43/14—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom six-membered rings
    • A01N43/16—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom six-membered rings with oxygen as the ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to the area teat dipping agents for lactating animals. More in particular it relates to a teat dipping agent based on components which are new within this technical area. This new teat dipping agent possesses several advantages in relation to known teat dipping agents.
  • Mastitis is an inflammatory reaction of udder tissue and is the most common and most costly disease among lactating cows over the world.
  • the inflammation is a reaction of the lactating tissues on the presence of infectious microorganisms.
  • a large number of different bacte- ria have been identified as mastitis pathogens. They have been divided into four different groups, contagious, environmental, opportunistic and other bacteria. The majority of the mastitis infections are caused by S . aureus .
  • Another contagious mastitis pathogen is Streptococcus aga la ctiae .
  • the environmental bacteria there are other streptococci and the coliform bacteria, such as- Es - cherichia coli and Klebsiella pneumoniae .
  • a large number of different disinfectants are used for dipping the teats immediately after milking in order to prevent bacteria from penetrating into the teat canal and further to lactating tissues.
  • These disinfectants have a killing effect in direct contact between disinfectant and bacterium.
  • the known agents are not sufficiently effective, v/hich can be due to insufficient amount of active components and the fact that the agents do not reach sufficient contact with the infected sites. It is also known that the effect of these agents fades out very quickly and that renewed contamination of the teats takes place shortly after the treatment.
  • iodine and chlorohexidin can result in taste changes of the milk and relatively small quantities of iodine and chlorohexidin in milk can cause problems in the manufacture of dairy products.
  • the present invention thus relates to a new teat dipping composition for lactating animals, which composition represents a substantial contribution to the tech- nology within the area since it has been found to show improvement in several respects compared to existing teat dipping compositions.
  • the composition according to the invention shows higher activity than, known teat dipping agents of the type chlorohexidin and iodophors.
  • An effect in this context is that the new teat dipping composition forms a long time barrier at the teat canal opening and prevents bacteria from penetrating into the teat canal.
  • the composition has a growth inhibiting effect on bacteria and a healing effect on skin wounds further strengthening the protection.
  • the composition can be used for a pure bacteria barrier or bacteriostatic effect, by which follows that it can be used as a prophylactic agent against as- titis.
  • the composition assists in the healing of wounds and skin fissures.
  • the composition can be given such consistency that it is easy to apply to the teats, for example by dipping or spraying, at the same time as it imparts a softening effect on the teats .
  • teat dipping in connection with the present invention shall be interpreted broadly and in accordance with the terminology used within this technical area.
  • the composition is not only intended for a dipping of the teats in same but it can, of course, also be applied in another way, such as by spraying, but still fall within the recognised term teat dipping composition or agent.
  • a first object of the invention is, with other words, to provide a teat dipping composition intended to be used for its bacteria barrier effect or bacteriostatic effect .
  • Another object of the invention is to provide a com- position which, when applied, results in a wound healing effect .
  • an object of the invention is to provide a com- position which, when applied, results in a prophylactic action against mastitis.
  • Another object of the invention is to provide a composition, which has such consistency that it is extremely well suited for dipping or spray application on the teats of lactating animals, at the same time as it thereby imparts a softening effect.
  • a further object of the invention is to provide a composition which assists in a faster and qualitatively improved healing of wounds on the teats.
  • the invention relates to use of a composition comprising chitosan in combination with a polysaccharide selected from heparin, heparan sulphate and dextran sulphate, as an active component in a solvent, for the manufacture of a teat dipping solution for lactating animals, particularly cows.
  • a composition comprising chitosan in combination with a polysaccharide selected from heparin, heparan sulphate and dextran sulphate, as an active component in a solvent, for the manufacture of a teat dipping solution for lactating animals, particularly cows.
  • composition according to the invention is useful for all kinds of lactating animals but, of course, in the first place cows. It is further presented in the form of a solution of the active component in a solvent, said so- lution with regard to consistency or viscosity generally being adapted to the method of application in a conventional manner.
  • the invention primarily is based on the specific combination of chitosan and the indicated polysaccharide and that primarily it is not restricted to any specific ratio between said components.
  • the ratio between the components and the total quantity of same in the solution are therefore, in other words, to be determined by the expert in each individual case depending on the effect desired.
  • composition comprises chitosan and the stated polysaccharide in such quantities that the solution when applied results in prophylactic effect against mastitis.
  • the invention is not restricted to any spe- cific total concentration of the active components it is generally suitable that the total concentration of chitosan plus polysaccharide in the solution is within the range 0.2-10, particularly 0.2-5, for example 0.25-3 percent by weight, based on the total weight of the solution, where the upper limit is mainly dictated by economic factors.
  • the weight ratio chitosan.polysaccharide in the composition according to the invention lies within the range 100:1 - 10:1, particularly 60:1 - 15:1.
  • chitosan With regard to the component chitosan it is consti- tuted by a polysaccharide consisting of 1.4- ⁇ -bound D- glucose a ine units. Said polysaccharide is linear and the properties can vary according to the degree of N- acetylation. In the nature all amino groups are acety- lated and the polysaccharide is then called chitin corre- sponding to the shell of inter alia insects and shellfish. Chitosan is manufactured by N-deacetylation of chitin. Commercially, chitosan is recovered from crab and shrimpshells which are waste products from the fishing industry.
  • N-deacetylation takes place, i.e. acetamido groups are converted into amino groups.
  • chito- sans of varying degree of N-acetylation can be manufactured.
  • said chitosan has an N-acetylation degree of at most about 90%.
  • said N- acetylation degree is at most about 50%, in some cases at most about 25%.
  • the polysaccharide used in the teat dipping composition according to the invention is selected from heparin, heparansulphate and dextransulphate, and these are commercially available on the market from several manufacturers.
  • these polysaccharides are, furthermore, partially hydrolysed forms of these polysaccharides as long as they essentially maintain the activity desired in the context.
  • RECTD7IED SHEET (RULE 91) polysaccharide shall, in other words, be interpreted broadly in connection with the invention.
  • the particularly preferred polysaccharide is, however, dextransul- phate since it shows very good activity at the same time as it is considerably cheaper than the other polysaccharides .
  • the composition according to the invention contains a conventional one, usually an aqueous carrier, for example pure water.
  • the solution is imparted suitable consistency or viscosity suitable for the application method used and this can be obtained according to conventional technology.
  • viscosity controlling agents for use in the composition according to the invention, there may be mentioned hemicellulose types, for example arabinoxy- lanes and glucomannanes ; plant gum materials, for example guar gum and johannistree gums; cellulose types and derivatives thereof, for example methyl cellulose, ethyl cellulose, hydroxyethyl cellulose or carboxymethyl cellu- lose; starch and starch derivatives, for example hydroxyethyl starch or crosslinked starch; microbial polysaccharides, for example xantan rubber, curdlan, pullulan or dextran; and glycerol.
  • Particularly preferred viscosity controlling agents are, however, different types of cellulose and derivatives thereof, particularly methyl cellulose
  • composition described above can be used as a barrier-forming teat dipping agent for lactating animals without any therapeutic effect
  • another aspect of the invention relates to the use of the composition as defined above as a barrier-forming or bacteriostatic teat dipping agent for lactating animals, particularly cows.
  • composition furthermore, can be utilised to counteract mastitis according to another aspect of the invention it represents the use of said composition for the manufacture of a teat dipping agent having prophylac-
  • a further aspect of the invention is represented by a method for prophylactic treatment of lactating animals, particularly cows, against mastitis, where on the teats of said animals a composition according to the above definition in a quantity effective for preventing the generation of mastitis is applied.
  • composition according to the invention can be prepared by dissolving the active components and, optionally, additives, such as for example viscosity controlling agents, in the selected solvent in the desired concentration.
  • additives such as for example viscosity controlling agents
  • An advantageous method in connection with the composition according to the invention resides in dis- solving chitosan and polysaccharide separately in a suitable quantity of solvent, for example about half each of the quantity solvent totally used.
  • the additives, for example the viscosity controlling agents are thereby dissolved together with the polysaccharide before both solu- tions of chitosan and polysaccharide are admixed to a common solution which is carefully admixed, for example in a mixer, to a final teat dipping solution. Examples
  • agar plates are covered with chitosan- dextransulphate solution before they are dipped in concentrated bacteria solutions and after said dipping.
  • Chi- tosan-dextransulphate is compared with commercial iodine solution used as a teat dipping agent, and the agar plates are treated in exactly the same manner with iodine solution.
  • the agar plates are incubated in a heating cabinet over night and the number of bacteria colonies are calculated and recorded as cfu/mL of the bacteria solution. Controls are untreated agar plates.
  • E-coli isolated from mastitis infection
  • E.coli and S.aureus and three different streptococci are sterile transferred (sterile bench) with loop from storage agar to separate sterilized trypton soy broth and incubated over night at 37°C in a shake incubator. The following morning the bacteria are washed three times with a physiological salt solution. The Optical density at 650 nm was measured with a photometer, and by means of standard curves the bacteria density was adjusted. Chitosan-dextran sulphate solution
  • chitosan 1 g was dissolved in 50 mL sterile water, and the pH was adjusted to 5.8.
  • 0.5 g glycerol and 0.1 g methylcellulose and 0.02 g dextransulphate were dissolved in 50 mL sterile water.
  • Equal amounts of chitosan solu- tion and glycerol + methyl cellulose + detransulphate solution were mixed in a mixer.
  • the base solution was diluted according to the in- struction 6 times with water for giving a solution for use .
  • Each bacterial type was treated separately according to the following:
  • Each type of bacterium was treated separately ac- cording to the following:
  • a teat dipping solution containing (percent by weight) 1% chitosan, 0.02 dextran sulphate, 0.1% methyl cellulose and 0.5% glycerol was prepared.
  • Milking was carried out at 07 30 and at 15 30 . Milk samples were taken directly after each milking situation for bacterial growth and analysis of the cell contents. The cell contents were determined with a fluoroop- toelectronic method (Fossomatic 90, A/S N. Foss Electric Denmark) . The bacteriological analysis was carried out by smearing 10 ⁇ l of the milk sample on to a bovine blood agar plate with esculine added and was incubated at 3-7°C for two days. Recordings were made after 24 and 48 hours and any mastitis pathogenic bacteria were isolated and identified. In connection with bacterial growth also routine CMT-analysis was made (California Mastit Test) . The study was carried out in three experimental rounds.
  • keratin was removed from the teat canal on all udder sections. This was done with a darning-needle (John James & Sons, Ltd, Studley, Warwickshire, size 16) . Keratin was removed from all teat canals after each morning milking.
  • the criterium for infection of an udder section was two subsequent milk samples having bacterial growth or increased cell contents.
  • a cow with symptom for acute clinical mastitis was treated with antibiotic and increased milking frequency.
  • ni number of infected non-treated udder sections
  • n 2 number of infected treated udder sections
  • Pi number of non-treated udder sections/ni
  • p 2 number of treated udder sections/n 2
  • Table 3 The number of infected udder sections after treatment with teat dipping agent compared with no teat dipping (control) . Experimental rounds 1 and 2 are assembled to one table.
  • control udder sections 7/12 were infected and of teat dipped udder sections 1/11 were infected.
  • Cow 334 was infected in all 3 udder sections part- taking in the experiment, 2 udder sections were controls and 1 udder section was treated. It was the treated udder section that became most infected and responded with a strong inflammatory reaction in the form of swelling, soreness and increased cell contents.
  • Streptococcus agalactiae was selected in order that the animals with high probability would not have been subjected to this bacterium earlier, it is easy to find in cultivation ( ⁇ -hemolysing) , it is strictly udder specific and it is documented sensitive to penicillin.
  • animals infected late in the first experiment were also infected late in the second experiment.
  • Cows Nos. 306 and 331 were teat dipped on right rear and left forward teat, respectively, cow No. 333 was teat dipped on right forward and left rear teat, respectively.
  • Cow No. 306 was teat dipped on right forward teat
  • 331 was teat dipped on right forward and right rear teat
  • 334 and 338 were teat dipped on right rear teat.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Lubricants (AREA)
  • Glass Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Use of a composition comprising chitosan in combination with a polysaccharide selected from heparin, heparan sulphate and dextran sulphate, as an active component in a solvent, for the manufacture of a teat dipping solution for lactating animals, particularly cows. The invention also relates to a process for prophylactic or wound healing treatment of lactating animals, particularly cows, against mastitis.

Description

TEAT DIPPING AGENT
Technical area
The present invention relates to the area teat dipping agents for lactating animals. More in particular it relates to a teat dipping agent based on components which are new within this technical area. This new teat dipping agent possesses several advantages in relation to known teat dipping agents.
Background of the invention Mastitis is an inflammatory reaction of udder tissue and is the most common and most costly disease among lactating cows over the world. The inflammation is a reaction of the lactating tissues on the presence of infectious microorganisms. A large number of different bacte- ria have been identified as mastitis pathogens. They have been divided into four different groups, contagious, environmental, opportunistic and other bacteria. The majority of the mastitis infections are caused by S . aureus . Another contagious mastitis pathogen is Streptococcus aga la ctiae . Among the environmental bacteria there are other streptococci and the coliform bacteria, such as- Es - cherichia coli and Klebsiella pneumoniae .
A large number of different disinfectants (most frequently chlorohexidine or iodophors) are used for dipping the teats immediately after milking in order to prevent bacteria from penetrating into the teat canal and further to lactating tissues. These disinfectants have a killing effect in direct contact between disinfectant and bacterium. In spite of routine use of these agents a number of bacteria escaped the killing effect, i.e. the known agents are not sufficiently effective, v/hich can be due to insufficient amount of active components and the fact that the agents do not reach sufficient contact with the infected sites. It is also known that the effect of these agents fades out very quickly and that renewed contamination of the teats takes place shortly after the treatment. Small wounds and skin tissues on the teats can act as reservoirs for certain bacteria, and live stock with infected teat wounds often show higher mastitis frequencies than other live stock. Furthermore, iodine and chlorohexidin can result in taste changes of the milk and relatively small quantities of iodine and chlorohexidin in milk can cause problems in the manufacture of dairy products.
Description of the invention
The present invention thus relates to a new teat dipping composition for lactating animals, which composition represents a substantial contribution to the tech- nology within the area since it has been found to show improvement in several respects compared to existing teat dipping compositions.
More in particular, it has, in accordance with the invention, surprisingly been found that a combination of chitosan and a group of polysaccharides functions quite well as active components in such teat dipping composition. Several different effects and advantages have been observed. Quite generally, it means that the composition according to the invention shows higher activity than, known teat dipping agents of the type chlorohexidin and iodophors. An effect in this context is that the new teat dipping composition forms a long time barrier at the teat canal opening and prevents bacteria from penetrating into the teat canal. Furthermore, the composition has a growth inhibiting effect on bacteria and a healing effect on skin wounds further strengthening the protection. This means that the composition can be used for a pure bacteria barrier or bacteriostatic effect, by which follows that it can be used as a prophylactic agent against as- titis. In addition, the composition assists in the healing of wounds and skin fissures. Furthermore, the composition can be given such consistency that it is easy to apply to the teats, for example by dipping or spraying, at the same time as it imparts a softening effect on the teats .
It can be added in this context with regard to prior art that a composition similar in composition is know per se from for example WO96/02260. However, this known composition has not been referred to or remotely indicated as a teat dipping composition, much less is there in the prior art any indication about the fact that it in such context even shows higher activity than known teat dipping agents of the type chlorohexidin and iodophors .
The expression teat dipping in connection with the present invention shall be interpreted broadly and in accordance with the terminology used within this technical area. Thus, the composition is not only intended for a dipping of the teats in same but it can, of course, also be applied in another way, such as by spraying, but still fall within the recognised term teat dipping composition or agent. A first object of the invention is, with other words, to provide a teat dipping composition intended to be used for its bacteria barrier effect or bacteriostatic effect .
Another object of the invention is to provide a com- position which, when applied, results in a wound healing effect .
Yet an object of the invention is to provide a com- position which, when applied, results in a prophylactic action against mastitis. Another object of the invention is to provide a composition, which has such consistency that it is extremely well suited for dipping or spray application on the teats of lactating animals, at the same time as it thereby imparts a softening effect. A further object of the invention is to provide a composition which assists in a faster and qualitatively improved healing of wounds on the teats. Other objects and advantages of the invention will be clear from the more detailed description thereof below.
Detailed description of the invention More in particular, the invention relates to use of a composition comprising chitosan in combination with a polysaccharide selected from heparin, heparan sulphate and dextran sulphate, as an active component in a solvent, for the manufacture of a teat dipping solution for lactating animals, particularly cows.
The composition according to the invention is useful for all kinds of lactating animals but, of course, in the first place cows. It is further presented in the form of a solution of the active component in a solvent, said so- lution with regard to consistency or viscosity generally being adapted to the method of application in a conventional manner.
From the above it is clear that the invention primarily is based on the specific combination of chitosan and the indicated polysaccharide and that primarily it is not restricted to any specific ratio between said components. The ratio between the components and the total quantity of same in the solution are therefore, in other words, to be determined by the expert in each individual case depending on the effect desired.
However, in accordance with the invention it is primarily a question of using the stated components in such quantities that the solution when applied results in a bacteria barrier effect or bacteriostatic effect. Yet another embodiment means that the composition comprises chitosan and the stated polysaccharide in such quantities that the solution when applied results in prophylactic effect against mastitis.
Although the invention is not restricted to any spe- cific total concentration of the active components it is generally suitable that the total concentration of chitosan plus polysaccharide in the solution is within the range 0.2-10, particularly 0.2-5, for example 0.25-3 percent by weight, based on the total weight of the solution, where the upper limit is mainly dictated by economic factors. According to a preferred embodiment of the invention the weight ratio chitosan.polysaccharide in the composition according to the invention lies within the range 100:1 - 10:1, particularly 60:1 - 15:1.
With regard to the component chitosan it is consti- tuted by a polysaccharide consisting of 1.4-β-bound D- glucose a ine units. Said polysaccharide is linear and the properties can vary according to the degree of N- acetylation. In the nature all amino groups are acety- lated and the polysaccharide is then called chitin corre- sponding to the shell of inter alia insects and shellfish. Chitosan is manufactured by N-deacetylation of chitin. Commercially, chitosan is recovered from crab and shrimpshells which are waste products from the fishing industry. When treating chitin with alkali, usually so- dium hydroxide, N-deacetylation takes place, i.e. acetamido groups are converted into amino groups. By controlling the conditions for this alkali treatment chito- sans of varying degree of N-acetylation can be manufactured. In connection with the invention said chitosan, according to a preferred embodiment, has an N-acetylation degree of at most about 90%. In particular, said N- acetylation degree is at most about 50%, in some cases at most about 25%. Accordingly, the polysaccharide used in the teat dipping composition according to the invention is selected from heparin, heparansulphate and dextransulphate, and these are commercially available on the market from several manufacturers. Within the framework of the inven- tion are, furthermore, partially hydrolysed forms of these polysaccharides as long as they essentially maintain the activity desired in the context. The expression
RECTD7IED SHEET (RULE 91) polysaccharide shall, in other words, be interpreted broadly in connection with the invention. The particularly preferred polysaccharide is, however, dextransul- phate since it shows very good activity at the same time as it is considerably cheaper than the other polysaccharides .
As a carrier or matrix the composition according to the invention contains a conventional one, usually an aqueous carrier, for example pure water. The solution is imparted suitable consistency or viscosity suitable for the application method used and this can be obtained according to conventional technology. As exemples of viscosity controlling agents for use in the composition according to the invention, there may be mentioned hemicellulose types, for example arabinoxy- lanes and glucomannanes ; plant gum materials, for example guar gum and johannistree gums; cellulose types and derivatives thereof, for example methyl cellulose, ethyl cellulose, hydroxyethyl cellulose or carboxymethyl cellu- lose; starch and starch derivatives, for example hydroxyethyl starch or crosslinked starch; microbial polysaccharides, for example xantan rubber, curdlan, pullulan or dextran; and glycerol. Particularly preferred viscosity controlling agents are, however, different types of cellulose and derivatives thereof, particularly methyl cellulose, and glycerol.
Since the composition described above can be used as a barrier-forming teat dipping agent for lactating animals without any therapeutic effect another aspect of the invention relates to the use of the composition as defined above as a barrier-forming or bacteriostatic teat dipping agent for lactating animals, particularly cows.
Since the composition, furthermore, can be utilised to counteract mastitis according to another aspect of the invention it represents the use of said composition for the manufacture of a teat dipping agent having prophylac-
RECTD7IED SHEET (RULE 91) tic action against mastitis of lactating animals, particularly cows.
A further aspect of the invention is represented by a method for prophylactic treatment of lactating animals, particularly cows, against mastitis, where on the teats of said animals a composition according to the above definition in a quantity effective for preventing the generation of mastitis is applied.
The composition according to the invention can be prepared by dissolving the active components and, optionally, additives, such as for example viscosity controlling agents, in the selected solvent in the desired concentration. An advantageous method in connection with the composition according to the invention resides in dis- solving chitosan and polysaccharide separately in a suitable quantity of solvent, for example about half each of the quantity solvent totally used. The additives, for example the viscosity controlling agents, are thereby dissolved together with the polysaccharide before both solu- tions of chitosan and polysaccharide are admixed to a common solution which is carefully admixed, for example in a mixer, to a final teat dipping solution. Examples
The invention will now be further illustrated by_ the following non-limiting examples.
Example 1
General procedure
Vertical agar plates are covered with chitosan- dextransulphate solution before they are dipped in concentrated bacteria solutions and after said dipping. Chi- tosan-dextransulphate is compared with commercial iodine solution used as a teat dipping agent, and the agar plates are treated in exactly the same manner with iodine solution. The agar plates are incubated in a heating cabinet over night and the number of bacteria colonies are calculated and recorded as cfu/mL of the bacteria solution. Controls are untreated agar plates.
Materials and reagents
E-coli, isolated from mastitis infection
(Mastitlaboratoriet, SVA)
S.aureus, isolated from mastitis infection
(Mastitlaboratoriet, SVA) Strept. agalactiae, Strept. dysgalactiae and Strept uberis, isolated from mastitis infection
(Mastitlaboratoriet, SVA)
Soy broth, Tryptic soy broth, Difco 0370-01-1
Verical agar plates, Uricult Orion UF009
Sterile bench, Kojair, LAF 7022
Photometer, Shimadzu UV-1201
Shake incubator, Orbit Environ-Shaker, Lab-Line In struments Inc. Heat cabinet, Memmert
NaCl, Riedel-de Haen 31434 Chitosan, Seacure 343, Pronova Biopolymer Acetic acid, Riedel-de Haen NaOH
Methyl cellulose, Sigma M-0387
Glycerol, Johnson Matthey Electronics 13797
Dextran sulphate, Pharmacia
Iodine solution, Dipal, Alfa Laval 997515-80
Procedure
E.coli and S.aureus and three different streptococci (Strept. agalactiae, Strept. dysgalactiae and Strept. uberis) are sterile transferred (sterile bench) with loop from storage agar to separate sterilized trypton soy broth and incubated over night at 37°C in a shake incubator. The following morning the bacteria are washed three times with a physiological salt solution. The Optical density at 650 nm was measured with a photometer, and by means of standard curves the bacteria density was adjusted. Chitosan-dextran sulphate solution
1 g chitosan was dissolved in 50 mL sterile water, and the pH was adjusted to 5.8. 0.5 g glycerol and 0.1 g methylcellulose and 0.02 g dextransulphate were dissolved in 50 mL sterile water. Equal amounts of chitosan solu- tion and glycerol + methyl cellulose + detransulphate solution were mixed in a mixer.
Iodine solution
The base solution was diluted according to the in- struction 6 times with water for giving a solution for use .
Bacteria tests
(i) Bacterial growth under chitosan-dextran sulphate film.
Each bacterial type was treated separately according to the following:
Three agar plates were lowered into the bacteria solution, and two of the agar plates were then dipped three times in each of the above solutions. One agar plate was left untreated.
(ii) Bactierial growth on top of chitosan-dextran sulphate film.
Each type of bacterium was treated separately ac- cording to the following:
Two agar plates were dipped three times in each of the above solutions. One agar plate was left untreated. All three agar plates were then immediately quenched in the bacteria solution. The agar plates were incubated over night in a heat cabinet at 37°C. Then the plates and the number of colonies were inspected and registered. Results Table 1
Bacterial growth under chitosan-dextran sulphate film Patogene CFU/mL
Chitosan - dextran sul-
Control phate Iodine
E. coli 10 000 000 0 0
S . aureus 1 000 000 0 0
Streptococci 10 000 000 0 0
Table 2
Bacterial growth on top of chitosan-dextran sulphate film Patogen CFU/mL
Chitosan dextran sul-
Controll phate Iodine
E. coli 10 000 000 0 10 000 000
S . aureus 1 000 000 0 1 000 000
Streptococci 10 0000 000 0 10 000 000
The results are presented in Figures 1 and 2.
Example 2
Materials and methods
6 cows of an age of 3-5 years were involved in the study. Five of the cows were of SRB-rase (Svensk Rod- brokig Boskap) and the sixth was a crossing between the SRB and SLB (Svensk Laglands Boskap) . The animals were acquired from one and the same stock and were bought 12 days before initiating the experiments. The cows were stabled and a maintenance ration of fodder was composed similar to the maintenance ration of fodder that the cows had had in their original stock. The maintenance ration of fodder consisted of hay, grass ensilage, rich food and concentrate. The cows were collared in long stalls with rubber mat and cutter shavings as a litter bed.
Five cows were in the first lactation and one cow was in its third lactation. The stage of lactation varied between the second to the seventh lactation month. The yield of milk in the start of the experiments varied between 28-48 kgs ECM. The udder health was documented to be good before the start of the experiments, with negative cultivation tests and CMT-values of 1 and 2. How- ever, coagulase negative staphylococci grew in one udder section (forward left) on one cow, together with increased cell contents (CMT 3) , in view of which this udder section was excluded from the experiment.
A teat dipping solution containing (percent by weight) 1% chitosan, 0.02 dextran sulphate, 0.1% methyl cellulose and 0.5% glycerol was prepared.
Milking was carried out at 0730 and at 1530. Milk samples were taken directly after each milking situation for bacterial growth and analysis of the cell contents. The cell contents were determined with a fluoroop- toelectronic method (Fossomatic 90, A/S N. Foss Electric Denmark) . The bacteriological analysis was carried out by smearing 10 μl of the milk sample on to a bovine blood agar plate with esculine added and was incubated at 3-7°C for two days. Recordings were made after 24 and 48 hours and any mastitis pathogenic bacteria were isolated and identified. In connection with bacterial growth also routine CMT-analysis was made (California Mastit Test) . The study was carried out in three experimental rounds. In the first experimental round the animals were divided up so that three cows with together 12 udder sections were teat-dipped diagonally right forward and left rear, and three cows were teat-dipped reversed diagonally, i.e. left forward and right rear (see Table 5) . The other 11 udder sections were left untreated as controls. To the second experimental round four of the cows having 10 udder sections not infected in the first experiment were used. The udder sections were randomly distributed so that five were treated with the new teat dip- ping agent and five constituted controls. Two cows contributed with 3 udder sections each and two udder sections each and the two others with two udder sections each, see Table 5.
For the third experimental round four of the cows were used with seven udder sections which had not become infected during the previous experimental rounds. All 7 udder sections were treated with commercial teat dipping agent containing iodine. Two cows contributed with one udder section each and the two others with 2 and 3 udder sections, respectively, each, see Table 8.
In order to make the udder sections more sensitive to infection during the experiment keratin was removed from the teat canal on all udder sections. This was done with a darning-needle (John James & Sons, Ltd, Studley, Warwickshire, size 16) . Keratin was removed from all teat canals after each morning milking.
In the first experimental round the keratin removal was terminated day 8. For two cows which up to day 7 had not become infected keratin removal was carried out both morning and night day 7 and 8.
In the second experimental round the keratin removal was terminated day 6, here double keratin removals did not have to be performed in order to infect the cows.
In the third experimental round the keratin removal was terminated day 8. Keratin removal was carried out both morning and night day 7 and 8.
Ten minutes after the teat dipping procedure all teats were dipped for 10 seconds in a bacteria suspension, containing about 1-7 x 107 CFU/ml of a β-hemolysing Streptococcus agalactiae strain (S-B8) .
The criterium for infection of an udder section was two subsequent milk samples having bacterial growth or increased cell contents. A cow with symptom for acute clinical mastitis was treated with antibiotic and increased milking frequency.
Experimental schedule Morning milking
1. After milking the teats were cleaned with 70% ethanol. The ethanol was allowed to evaporate and milk samples were then taken in test tubes from each udder quarter.
2. The teats were then carefully washed with 70% ethanol. A sterile darning-needle was inserted into the teat canal, rotated and then withdrawn. All teats were treated in this manner.
3. The pre-determined teats were immediately after point 2 dipped with teat dipping agent. The control teats were left untreated. 4. After 10 minutes all teats were dipped for 10 seconds in the bacterium suspension with 1-7 x 107 CFU/ml of β-hemolysing Streptococcus aga lactiae.
Night milking
1. After milking the teats were cleaned with 70% ethanol. The ethanol was allowed to evaporate and milk samples were then taken in test tubes from each udder quarter. 2. The predetermined teats were dipped immediately after point 1 with teat dipping agent. The control teats were left untreated.
3. After 10 minutes all teats were dipped in bacterium suspension for 10 seconds.
Statistic evaluation has been made by means of χ2- analysis according to the following formula. (O - Ey
and 95% confidence interval was calculated by means of the formula
(pl - p2 ) ± 1 , 96 x _«?(/?, - p. )
wherein se(pl - p2 ) has been calculated as
Figure imgf000016_0001
se = standard error ni = number of infected non-treated udder sections n2 = number of infected treated udder sections Pi = number of non-treated udder sections/ni p2 = number of treated udder sections/n2
Results In total 14 of the 33 udder sections were infected during the two experimental rounds, of these were 12 not teat dipped and two were teat dipped. All cows in experimental rounds 1 and 2 became infected. In experimental round 3 two of the cows became infected. The number of days between start of experiments and up to infection of udder sections varied between 2 and 9 days .
Table 3 The number of infected udder sections after treatment with teat dipping agent compared with no teat dipping (control) . Experimental rounds 1 and 2 are assembled to one table.
RECTDTED SHEET (RULE 91) Treated Control Total
Infected 2 12 14
Not in14 5 19 fected
Total 16 17 33
Table 4 The number of infected udder sections after treatment with commercial teat dipping agent. Experimental round 3.
Treated
Infected 2 Not infec 5
Total 7
Experimental round 1
Of the control udder sections 7/12 were infected and of teat dipped udder sections 1/11 were infected.
Five cows were infected with Streptococcus agalac- tiae in one udder section, the udder sections infected were controls .
One cow (No. 335) was infected in 3 udder sections, 2 control udder sections and 1 teat dipped udder section. The udder section of cow 335 which was strongly infected and reacted with the highest cell contents in the milk was one control section, see tables 5 and 6.
Experimental round 2
Out of the control udder sections 5/5 were infected and out of teat dipped udder sections 1/5 were infected, see table 7.
Cow 334 was infected in all 3 udder sections part- taking in the experiment, 2 udder sections were controls and 1 udder section was treated. It was the treated udder section that became most infected and responded with a strong inflammatory reaction in the form of swelling, soreness and increased cell contents.
The other three cows in the experiment were infected in one control udder section each, see table 7.
Experimental round 3 Out of the 7 udder sections treated with commercial iodine teat dipping agent, 2 udder sections were infected, see Table 8.
The result of the χ2-analysis for the assembled experimental results from rounds 1 and 2 gave an χ2-value of 11.39, which corresponds to a probability value of
< 0.1% at one degree of liberty. I.e., the probability to obtain such a deviating value as 11.39, if h0 (the zero hypothesis) starts from the assumption that there is no difference between treated and untreated group, is less than 0.1%.
When calculating 95% confidence interval for the difference in proportion ( i - p2) between the two experimental groups the result was 0.581 ± 1.96 x 0.138, i.e. between 0.311 and 0.851. Only 7 udder sections were part of experimental round 3. These were constituted by udder sections resisting infection for the longest period of time and were therefore the result of a selection. In view of this no statistic evaluation of this experimental round was made. The infection frequency of the different experimental rounds is summarized in Figure 3.
Discussion
All cows originated from the same live stock and had thereby the same immunological background. This was an advantage since one could expect that the cows would react in essentially the same manner during the readjust- ent period to the new environment including new maintenance ration of fodder. This resulted, together with the maintenance ration of fodder that was similar to that the cows were used to, in a situation whereby the time for buying the cows to the start of the experiments could be kept short (by 10 days) .
Streptococcus agalactiae was selected in order that the animals with high probability would not have been subjected to this bacterium earlier, it is easy to find in cultivation (β-hemolysing) , it is strictly udder specific and it is documented sensitive to penicillin.
The cows which were infected in 1 udder section in experimental rounds 1 and 2 became so in the untreated udder section, whereas the cows receiving infection in teat dipped udder sections became simultaneously infected in untreated udder sections.
In order to increase the infection risk of two cows which in the first experimental round were not infected up to day 7, the removal of keratin was extended to two times a day. The rate of generation of teat canal keratin is high (12-36h) and probably varies between individuals in view of which they have different sensibility for similar challenges in this context. Also the quantity of keratin, the majority of the keratin and composition - thereof can vary between individuals.
It can be noted that animals infected late in the first experiment were also infected late in the second experiment.
RECTD7IED SHEET (RULE 91) Table 5. Analysis results of cell contents, CMT and bacterial growth in cows Nos. 306, 331 and 333 from the first experiment round. Cows Nos. 306 and 331 were teat dipped on right rear and left forward teat, respectively, cow No. 333 was teat dipped on right forward and left rear teat, respectively.
Figure imgf000020_0001
am=morning Hf=right forward teat Vb=left rear teat pm=afternoon Hb=right rear teat Vf=left forward teat Cell cont=counted in 1000;CMT=California Mastitis Test;
10 Bact .growth, Sr=Streptococcus agalactiae, S=Staphylococcus spp. ;E=Ethacilin;#=teat-dipped;N=Novocillin Table 5 cont.
RECTDTDXD SHEET (RULE 91) Table 5 cont.
Figure imgf000021_0001
am=morn ng Hf=r ght forward teat Vb=left rear teat pm=afternoon Hb=right rear teat Vf=left forward teat Cell cont=counted in 1000;CMT=California Mastitis Test; Bact .growth, Sr=Streptococcus agalactiae, S=Staphylococcus spp. ;E=Ethacilin;»=teat-dipped;N=Novocillin
Table 5 cont.
RECTD7HCD SHEET (RULE 91)
Figure imgf000022_0001
am=morning Hf=right forward teat Vb=left rear teat pm=afternoon Hb=right rear teat Vf=left forward teat Cell cont=counted in 1000; CMT=California Mastitis Test; Bact . growth, Sr=Streptococcus agalactiae, S=Staphylococcus spp. ;E=Ethacilin; ,=teat-dipped;N=Novocillin
RECTDTπCD SHEET (RULE 91) Table 6. Analysis results of cell contents, CMT and bacterial growth in cow Nos. 334, 335 and 338 from the first experiment round. Cow Nos. 306 and 335 were teat dipped on right forward and left rear teat, respectively, cow No. 338 was teat dipped on right rear and left forward teat, respectively.
Figure imgf000023_0001
am=morning Hf=rιght forward teat Vb=left rear teat pm=afternoon Hb=right rear teat Vf=left forward teat Cell cont=counted in 1000; CMT=California Mastitis Test;Bact .growth, Sr=Streptococcus agalactiae, S=Staphylococcus spp. ;E=Ethacilin; •=teat-dipped;N=Novocillin
Table 6 cont.
Figure imgf000024_0001
am=morning Hf=right forward teat Vb=left rear teat pm=afternoon Hb=right rear teat Vf=left forward teat Cell cont=counted in 1000;CMT=California Mastitis Test; Bact. growth, Sr=Streptococcus agalactiae, S=Staphylococcus spp. ;E=Ethacilin;*=teat-dipped;N=Novocillin
Table 6 cont.
RECTD7IED SHEET (RULE 91)
Figure imgf000025_0001
am=morning Hf=right forward teat Vb=left rear teat pm=afternoon Hb=right rear teat Vf=left forward teat Cell cont=counted in 1000;CMT=California Mastitis Test; Bact . growth, Sr=Streptococcus agalactiae, S=Staphylococcus spp. ;E=Ethacilin; •=teat-dipped;N=Novocillin
RECTDTED SHEET (RULE 91) Table 7. Analysis results of cell contents, CMT and bacterial growth in cow Nos. 306, 331, 334 and 338 from the second experiment round. Cow No. 306 was teat dipped on right forward teat, 331 was teat dipped on right forward and right rear teat, respectively, 334 and 338 were teat dipped on right rear teat.
Figure imgf000026_0001
am=morning Hf=right forward teat Vb=left rear teat pm=afternoon Cell cont=in 1000;CMT=California Mastitis Test; Bact .growth, Sr=Streptococcus agalactiae, S=Staphylococcus spp. ;E=Ethacilin; •=teat-dipped;N=Novocillin Table 7 cont.
RECTD7D2D SHEET (RULE91)
Figure imgf000027_0001
am=morning Hf=right forward teat Vb=left rear teat pm=afternoon Hb=right rear teat Vf=left forward teat Cell cont=counted in 1000;CMT=California Mastitis Test; Bact .growth, Sr=Streptococcus agalactiae; S=Staphylococcus spp. ;E=Ethacilin; •=teat-dipped;N=Novocillin Table 8. Analysis results of cell contents, CMT and bacterial growth in cow Nos. 306, 331, 333 and 335 from the third ex- periment round with commercial teat dipping composition. Cow No. 306 was teat dipped on right forward teat, cow No. 331 on right forward and right rear teat, respectively, cow No. 333 on right forward, left rear teat and left forward teat, re- spectively, and cow No. 335 on left rear teat..
Figure imgf000028_0001
am=morning Hf=right forward teat Vb=left rear teat pm=afternoon Hb-right rear teat Vf=left forward teat Cell cont=counted in 1000;CMT=California Mastitis Test; Bact .growth, Sr=Streptococcus agalactiae, S=Staphylococcus spp. ;E=Ethacilin; Table 8 cont.
Figure imgf000029_0001
am=morning Hf=right forward teat Vb=left rear teat pm=afternoon Hb-right rear teat Vf=left forward teat Cell cont=counted in 1000;CMT=California Mastitis Test; Bact . growth, Sr=Streptococcus agalactiae, S=Staphylococcus spp. ;E=Ethacilin; Table 8 cont.
98/48627
28
Figure imgf000030_0001
am=morning Hf=right forward teat Vb=left rear teat pm=afternoon Hb=right rear teat Vf=left forward teat Cell cont=counted in 1000;CMT=California Mastitis Test;Bact .growth, Sr=Streptococcus agalactiae, S=Staphylococcus spp . ; E=Ethacilin;
T RULE91)

Claims

1. Use of a composition comprising chitosan in combination with a polysaccharide selected from heparin, heparan sulphate and dextran sulphate, as an active com- ponent in a solvent, for the manufacture of a teat dipping solution for lactating animals, particularly cows, .
2. Use according to claim 1, characterized in that the composition comprises chitosan and said polysaccharide in such quantities that the solution when applied results in a bacterial barrier or bacteriostatic effect.
3. Use according to claim 1, characterized in that the composition comprises chitosan and polysaccharide in such quantities that the solution when applied results in a wound healing effect.
4. Use according to claim 1, characterized in that the composition comprises chitosan and polysaccharide in such quantities that the solution when applied results in a prophylactic effect against mastitis.
5. Use according to any preceding claim, character- ized in that the total concentration of chitosan plus polysaccharide in the solution lies within the range 0.2- 10, particularly 0.2-5, for example 0.25-3 percent by weight, based on the weight of the solution.
6. Use according to any preceding claim, character- ized in that the weight ratio chitosanipolysaccharide lies within the range 100:1 - 10:1.
7. Use according to claim 6, characterized in that said weight ratio lies within the range 60:1 - 15:1.
8. Use according to any preceding claim, character- ized in that the polysaccharide is dextran sulphate.
9. Use according to any preceding claim, characterized in that said chitosan has a degree of N-acetylation of at most about 90%.
10. Use according to claim 9, characterized in that said degree of N-acetylation is at most about 50%, preferably at most about 25%. -.- .-,^ 98/48627
30
11. Use according to any preceding claim, characterized in that the solvent is water based, preferably water.
12. Use according to any preceding claim, character- ized in that the solution contains a viscosity controlling agent selected from cellulose derivatives, particularly methyl cellulose, and glycerol, particularly in such quantities that the solution is applicable by dipping or spraying.
13. A process for prophylactic or wound healing treatment of lactating animals, particularly cows, against mastitis, where a composition comprising chitosan in combination with a polysaccharide selected from heparin, heparan sulphate and dextran sulphate, as an active component in a solvent, is applied on the teats of said animals in a quantity effective for preventing mastitis.
14. A process according to claim 13, characterized in that the composition is as defined in anyone of claims 5 - 12.
TΠTEDSHEET(RULE9i)
PCT/SE1998/000776 1997-04-29 1998-04-28 Teat dipping agent Ceased WO1998048627A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
BR9804875-9A BR9804875A (en) 1997-04-29 1998-04-28 Use of a composition and procedure for prophylactic or wound healing of lactating animals.
PL98330870A PL330870A1 (en) 1997-04-29 1998-04-28 Teats soaking agent
US09/202,930 US6630458B2 (en) 1997-04-29 1998-04-28 Teat dipping agent
CA002259327A CA2259327A1 (en) 1997-04-29 1998-04-28 Teat dipping agent
AU73548/98A AU721692B2 (en) 1997-04-29 1998-04-28 Teat dipping agent
EP98920795A EP0917427B1 (en) 1997-04-29 1998-04-28 Teat dipping agent
DK98920795T DK0917427T3 (en) 1997-04-29 1998-04-28 teat
NZ333511A NZ333511A (en) 1997-04-29 1998-04-28 Teat dipping agent comprising chitosan and a polysaccharide
JP10546900A JP2000515897A (en) 1997-04-29 1998-04-28 Teat dip
AT98920795T ATE223649T1 (en) 1997-04-29 1998-04-28 MEANS FOR DIMMING TEATS
DE69807818T DE69807818T2 (en) 1997-04-29 1998-04-28 MEANS TO IMMERSE TITS
BG103034A BG64027B1 (en) 1997-04-29 1998-12-23 Form for teat immersion

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9701616A SE508760C2 (en) 1997-04-29 1997-04-29 Use of a composition comprising chitosan in combination with a polysaccharide, as an active component in a solvent, for the preparation of a dairy dipping agent for milk producing animals
SE9701616-6 1997-04-29

Publications (1)

Publication Number Publication Date
WO1998048627A1 true WO1998048627A1 (en) 1998-11-05

Family

ID=20406772

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1998/000776 Ceased WO1998048627A1 (en) 1997-04-29 1998-04-28 Teat dipping agent

Country Status (17)

Country Link
US (1) US6630458B2 (en)
EP (1) EP0917427B1 (en)
JP (1) JP2000515897A (en)
CN (1) CN1225555A (en)
AT (1) ATE223649T1 (en)
AU (1) AU721692B2 (en)
BG (1) BG64027B1 (en)
BR (1) BR9804875A (en)
CA (1) CA2259327A1 (en)
DE (1) DE69807818T2 (en)
DK (1) DK0917427T3 (en)
ES (1) ES2183359T3 (en)
HU (1) HUP0000754A3 (en)
NZ (1) NZ333511A (en)
PL (1) PL330870A1 (en)
SE (1) SE508760C2 (en)
WO (1) WO1998048627A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023085A1 (en) * 1998-10-19 2000-04-27 Novogen Research Pty. Ltd. Mastitis treatment with particulate glucan
WO2002083104A1 (en) * 2001-04-12 2002-10-24 Medicarb Ab An effervescent solid composition of matter
WO2003051376A1 (en) * 2001-12-14 2003-06-26 Ism Biopolymer Inc. Chitosan oligosaccharides and uses thereof
WO2003054208A3 (en) * 2001-12-13 2003-10-09 Ism Biopolymer Inc Method of modulating release of saccharides and uses thereof
AU2002233873B2 (en) * 2001-02-26 2004-05-06 Medicarb Ab Prophylactic teat treatment
US6896902B2 (en) 2001-04-12 2005-05-24 Medicarb Ab Effervescent solid composition of matter
WO2011109469A1 (en) * 2010-03-03 2011-09-09 Neocutis Sa Compositions and methods for treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds
US8226969B2 (en) 2006-08-18 2012-07-24 Massey University Methods for reducing the incidence of mastitis
EP2391209A4 (en) * 2009-01-27 2014-03-26 Teleflex Medical Inc EXPECTORING ASPIRATION AND DISSOLUTION SOLUTION FOR ENDOTRACHEAL PROBE AND TRACHEOSTOMY PROBE
CN104430395A (en) * 2014-10-30 2015-03-25 山东中大药业有限公司 Compound missible oil for preventing and treating cabbage plutella xylostella
WO2016040873A1 (en) * 2014-09-12 2016-03-17 Ccd Holdings Llc Method for the treatment, control, minimization, and prevention of bovine mastitis
US9737047B2 (en) 2011-03-22 2017-08-22 Ccd Holdings Llc Method for the treatment, control, minimization, and prevention of bovine mastitis
US9999198B2 (en) 2011-03-22 2018-06-19 Ccd Holdings Llc Animal bedding and associated methods for preparing and using the same

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180015A1 (en) * 2002-01-07 2004-09-16 Kross Robert D. Long-acting disinfecting nitrous acid compositions and related processes
US7968122B2 (en) 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
US8778369B2 (en) * 2005-07-29 2014-07-15 Delaval Holding Ab Barrier film-forming compositions and methods of use
US20070142322A1 (en) * 2005-12-20 2007-06-21 Kaspar Charles W Method of using chitosan to reduce shedding of E. coli from bovines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995030403A1 (en) * 1994-05-04 1995-11-16 Medicarb Ab Oral hygiene composition
WO1996002260A1 (en) * 1994-07-19 1996-02-01 Medicarb Ab Wound healing agent

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0285357A3 (en) * 1987-03-31 1989-10-25 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Control of retroviruses
JP3205104B2 (en) 1992-01-20 2001-09-04 川研ファインケミカル株式会社 Cosmetics
RU2048473C1 (en) 1992-12-25 1995-11-20 Гамзазаде Ариф Исмаилович Method of preparing interpolymeric complexes of chitosan with sodium dextran sulfate
SE9300139L (en) 1993-01-19 1994-07-20 Medicarb Ab Preparation of a new drug
SE507028C2 (en) 1996-08-06 1998-03-16 Medicarb Ab New medical use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995030403A1 (en) * 1994-05-04 1995-11-16 Medicarb Ab Oral hygiene composition
WO1996002260A1 (en) * 1994-07-19 1996-02-01 Medicarb Ab Wound healing agent

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023085A1 (en) * 1998-10-19 2000-04-27 Novogen Research Pty. Ltd. Mastitis treatment with particulate glucan
AU2002233873B2 (en) * 2001-02-26 2004-05-06 Medicarb Ab Prophylactic teat treatment
WO2002083104A1 (en) * 2001-04-12 2002-10-24 Medicarb Ab An effervescent solid composition of matter
US6896902B2 (en) 2001-04-12 2005-05-24 Medicarb Ab Effervescent solid composition of matter
US7153492B2 (en) 2001-04-12 2006-12-26 Medicarb Ab Effervescent solid composition of matter
WO2003054208A3 (en) * 2001-12-13 2003-10-09 Ism Biopolymer Inc Method of modulating release of saccharides and uses thereof
WO2003051376A1 (en) * 2001-12-14 2003-06-26 Ism Biopolymer Inc. Chitosan oligosaccharides and uses thereof
US8226969B2 (en) 2006-08-18 2012-07-24 Massey University Methods for reducing the incidence of mastitis
EP2391209A4 (en) * 2009-01-27 2014-03-26 Teleflex Medical Inc EXPECTORING ASPIRATION AND DISSOLUTION SOLUTION FOR ENDOTRACHEAL PROBE AND TRACHEOSTOMY PROBE
WO2011109469A1 (en) * 2010-03-03 2011-09-09 Neocutis Sa Compositions and methods for treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds
US9629856B2 (en) 2010-03-03 2017-04-25 Anteis Sa Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds
US9737047B2 (en) 2011-03-22 2017-08-22 Ccd Holdings Llc Method for the treatment, control, minimization, and prevention of bovine mastitis
US9999198B2 (en) 2011-03-22 2018-06-19 Ccd Holdings Llc Animal bedding and associated methods for preparing and using the same
WO2016040873A1 (en) * 2014-09-12 2016-03-17 Ccd Holdings Llc Method for the treatment, control, minimization, and prevention of bovine mastitis
CN104430395A (en) * 2014-10-30 2015-03-25 山东中大药业有限公司 Compound missible oil for preventing and treating cabbage plutella xylostella
CN104430395B (en) * 2014-10-30 2016-08-24 青岛青知企业管理咨询有限公司 A kind of compounded cream for preventing and treating Caulis et Folium Brassicae capitatae diamondback moth

Also Published As

Publication number Publication date
US20020103159A1 (en) 2002-08-01
SE9701616L (en) 1998-10-30
BG103034A (en) 1999-10-29
ES2183359T3 (en) 2003-03-16
PL330870A1 (en) 1999-06-07
CA2259327A1 (en) 1998-11-05
US6630458B2 (en) 2003-10-07
CN1225555A (en) 1999-08-11
EP0917427A1 (en) 1999-05-26
BG64027B1 (en) 2003-11-28
NZ333511A (en) 2000-06-23
DE69807818T2 (en) 2003-01-16
HUP0000754A3 (en) 2000-11-28
EP0917427B1 (en) 2002-09-11
SE508760C2 (en) 1998-11-02
AU721692B2 (en) 2000-07-13
BR9804875A (en) 2000-01-25
HUP0000754A2 (en) 2000-07-28
DE69807818D1 (en) 2002-10-17
DK0917427T3 (en) 2002-10-07
JP2000515897A (en) 2000-11-28
SE9701616D0 (en) 1997-04-29
ATE223649T1 (en) 2002-09-15
AU7354898A (en) 1998-11-24

Similar Documents

Publication Publication Date Title
EP0917427B1 (en) Teat dipping agent
KR100284081B1 (en) Iodine Barrier Nipple Dip
US6254881B1 (en) Antiinfective free intramammary veterinary composition
JPH07504918A (en) Chlorine dioxide-containing composition for the prevention and treatment of bacterial infections
CN112315842B (en) Dog and cat oral care spray containing lysozyme and preparation method thereof
CN111213786B (en) Water quality acidulant for preventing and controlling African swine fever as well as preparation method and application thereof
CN110013472A (en) A kind of milk cow teat film-forming medicated bath agent, its preparation method and its use method
Zhang et al. Evaluation of a povidone-iodine and chitosan-based barrier teat dip in the prevention of mastitis in dairy cows
CN102405935A (en) Protamine compound preparation and preparation method and application thereof
Hunter 391. The effect of penicillin in milk on the manufacture of Cheddar cheese
US20200046661A1 (en) Volatile Organic Compound Formulations Having Antimicrobial Activity
CN104224824A (en) Iodine disinfection solution for preventing and treating freshwater biological virus erosion
WO1995020968A1 (en) Prophylatic for domestic animal mastitis
JP2648886B2 (en) How to Prevent Household Mastitis
CN110583646A (en) Foam type subacid electrolyzed water disinfectant for chicken farm
MXPA99000221A (en) Teat dipping agent
KR100424339B1 (en) Dried fishes coated with chitosan and preparing method thereof
AU2002233873B2 (en) Prophylactic teat treatment
US4782048A (en) Method for treating or preventing bovine mastitis
CN115350270B (en) Lysostaphin emulsion protecting film preparation and preparation process thereof
CN111265498A (en) Film-forming povidone iodine solution and preparation method and application thereof
AU2002233873A1 (en) Prophylactic teat treatment
EP0692253A1 (en) Prophylatic for domestic animal mastitis
KR100299669B1 (en) Solution for sterilization of nipple and prevention of mastitis in dairy cows
JP2002187853A (en) Animal teat disinfectant and method for improving bacterial environment

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98800555.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1998920795

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 73548/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2259327

Country of ref document: CA

Ref document number: 2259327

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 333511

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/000221

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 09202930

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1998920795

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 73548/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998920795

Country of ref document: EP